Products

Our pipeline: Delivering first-in-class immunotherapies of activation and regulation

 

Four clinical assets

  • Immuno-Oncology
  • Immuno-Inflammation
Product candidate
Indication (targets)
Research
IND-enabling
Phase 1
Phase 2
Phase 3
Tedopi®
NSCLC post-ICI
Tedopi®
NSCLC Combo 2L post-ICI
Tedopi®
PDAC Combo maintenance
Tedopi®
OC Mono or Combo
OSE-127/Lusvertikimab
UC
OSE-279
Solid tumors
FR104
KIdney transplant
BI 765063
HNSCC 2L and HCC 1L/2L
BI 770371
Solid tumors
OSE-230 chemR23 mAb agonist
Inflammation diseases
BiCKI® PD1xIL-7
Immuno-Oncology
CLEC-1 antagonist
Immuno-Oncology

Significant partnerships with Boehringer Ingelheim, Veloxis Pharmaceuticals and CKD for up to €1.4Bn in milestones (€121 M already received since 2016)

Our portfolio of clinical assets and research platforms

In Immuno-Oncology and Immuno-Inflammation

Our portfolio of clinical assets and research platforms

Immuno-Oncology

Immuno-Inflammation

Preclinical platforms

T-cell activation through neo-epitopes
Transforming tumor micro-environement suppressive cells into effector cells

Down regulating T effector cells to decrease immunological reactivity
Up-regulating regulatory T-cells to develop immune tolerance

Two proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapies
Read more
Read more
Read more

Immuno-Oncology

T-cell activation through neo-epitopes
Transforming tumor micro-environement suppressive cells into effector cells

Read more

Immuno-Inflammation

Down regulating T effector cells to decrease immunological reactivity
Up-regulating regulatory T-cells to develop immune tolerance

Read more

Preclinical platforms

Two proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapies

Read more

To receive OSE Immunotherapeutics’ latest news